Načítá se...
MET Inhibitors for the Treatment of Gastric Cancer: What’s Their Potential?
Gastric cancer remains a disease with a dismal prognosis. Extensive efforts to find targetable disease drivers in gastric cancer were implemented to improve patient outcomes. Beyond anti-HER2 therapy, MET pathway seems to be culprit of cancer invasiveness with MET-overexpressing tumors having poorer...
Uloženo v:
| Vydáno v: | J Exp Pharmacol |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Dove
2020
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7547764/ https://ncbi.nlm.nih.gov/pubmed/33116950 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/JEP.S242958 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|